Mikrogen’s ELISA/BLOT assays help to gain insights into COVID-19 immunity

Intro tekst

To further contain the pandemic and gain more insight into the immunity patients developo as a result of a SARS-CoV-2 infection, Mikrogen has further expanded its range of diagnostics products for COVID-19. In addition to the molecular tests, serological tests are now also available.

Afbeelding

recomWell SARS-CoV-IgG
Code M-7304 (96 tests)

recomWell SARS-CoV-IgA
Code M-7305 (96 tests)

Benefits

  • Very high sensitivity and specificity due to the use of highly purified recombinant nucleocapsid antigen
  • Easy test procedure in the automatable ELISA screening format; quantitative results
  • Identical processing as well as uniform and interchangeable reagents for all MIKROGEN recomWell ELISA
  • Break-aparts: single sample examination possible
  • CE label: The recomWell SARS-CoV-2 IgG, IgA tests meet the high standards of the European directive 98/79/EC on in vitro diagnostic medical devices

Website manufacturer recomWell


recomLine SARS-CoV-IgG (Avidity)
Code M-7374 (20 tests)

Benefits
Use of different, recombinant SARS-CoV-2-specific antigens

Nucleocapsid (NP) as well as RBD and S1 of the spike protein:

•    Very high immunogenicity
•    Application in most screening assays

Additional information thanks to:
•    Detection of antibodies against seasonal coronaviruses (HCoV)
•    Possible avidity determination

Easy handling:
•    Identical processing as for other tests from the recomLine product line
•    Manual to fully automated workflow and evaluation possible

Website manufacturer recomLine